Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.42 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.42 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | ACE | P12821 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14638414 | 0.91 | CYP3A4 (0.45) | NR1H2CYP11B1CYP11B2KDM4EALDH1A1 | |
| SCHEMBL14637814 | 0.91 | CYP3A4 (0.45) | NR1H2CYP11B1CYP11B2KDM4EALDH1A1 | |
| SCHEMBL9347804 | 0.87 | NR1H2 (0.49) | NR1H2KDM4EALDH1A1KMT2AL3MBTL1 | |
| SCHEMBL15115348 | 0.86 | NR1H2 (0.43) | NR1H2CYP11B1CYP11B2KDM4EALDH1A1 | |
| SCHEMBL25409509 | 0.81 | SIGMAR1 (0.42) | ALDH1A1ACE | |
| SCHEMBL9347282 | 0.79 | FKBP1A (0.53) | KDM4EALDH1A1KMT2ACYP3A4 | |
| SCHEMBL23043376 | 0.79 | FKBP1A (0.53) | KDM4EALDH1A1KMT2ACYP3A4 | |
| SCHEMBL12480874 | 0.78 | GRM6 (0.43) | LMNAKMT2AACE | |
| SCHEMBL25409528 | 0.78 | ALDH1A1 (0.37) | KDM4EALDH1A1LMNAKMT2AL3MBTL1 | |
| SCHEMBL4710674 | 0.78 | GRM6 (0.49) | ALDH1A1LMNAKMT2AL3MBTL1ACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8815909-B2 | Diaminocyclohexane compounds and uses thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-08-26 | — | — | US | disclosed |
| US-20130184284-A1 | DIAMINOCYCLOHEXANE COMPOUNDS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2013-07-18 | — | — | US | disclosed |
| WO-2013012827-A1 | DIAMINOCYCLOHEXANE COMPOUNDS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130184284-A1 | DIAMINOCYCLOHEXANE COMPOUNDS AND USES THEREOF | NPY4R, NPY2R, NPY1R | NR1H2 318/4885CYP11B1 421/4885CYP11B2 347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.